We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
- Authors
Zozaya, Néboa; Arrizubieta Basterrechea, Maria Iciar; Bollo, Elena; Castellví, Iván; Espín, Jaime; Ortego, Norberto; Poveda-Andrés, José Luis; Rodríguez Portal, José Antonio; Rivero, Agustín; Marcos-Rodríguez, José Antonio; Verde, Luis
- Abstract
Objectives: Our aim was to assess the value of nintedanib for non-idiopathic progressive fibrosing interstitial lung disease (non-IPF PF-ILD) and systemic sclerosis-associated ILD (SSc-ILD) in the Spanish context, using a multi-criteria decision analysis (MCDA). Methods: Following an adaptation of the Evidence and Value: Impact on DEcision Making (EVIDEM) MCDA methodology, the estimated value of nintedanib was obtained by means of an additive linear model that combined individual weights (100-points distribution) of criteria with the individual scoring of nintedanib in each criterion for every indication, assigned by a multidisciplinary committee of twelve clinicians, patients, pharmacists, and decision-makers. To assess the reproducibility, an alternative weighting method was applied, as well as a re-test of weights and scores at a different moment of time. Results: The experts committee recognized nintedanib as an intervention with a positive value contribution in comparison to placebo for the treatment of non-IPF PF-ILD (0.50 ± 0.16, on a scale from −1 to 1) and SSc-ILD (0.40 ± 0.12), diseases which were considered as very severe and with high unmet needs. The drug was perceived as a treatment that provides an added therapeutic benefit for patients (0.06–0.07), given its proven clinical efficacy (0.05–0.06), slight improvements in patient-reported outcomes (0.01–0.02), and similar safety profile than placebo (−0.04–0.00), which will likely be positioned as a recommended therapy in the next clinical practice guidelines updates. Conclusions: Under this increasingly used methodology, nintedanib has shown to provide a positive value estimate for non-IPF PF-ILD and SSc-ILD when compared to placebo in Spain.
- Publication
International Journal of Technology Assessment in Health Care, 2021, Vol 38, Issue 1, p1
- ISSN
0266-4623
- Publication type
Article
- DOI
10.1017/S0266462322000459